logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
BackJournal Details
Pharmacoeconomics cover

Pharmacoeconomics

IF4.6
Papers231
Citations7336
Journal Papers 206
Publication Date
delete
Correction: Comparing User‑Written Codes for Performing Economic Evaluations in Stata
deletePharmacoeconomics
IF4.6
delete2026-10-06
delete0
PREAI
deleteBradley Barker-Jones; Patricia Navvuga; Petra Baji; Elsa M. R. Marques; William Hollingworth
deleteShare
deleteSave
Methods in Systematic Reviews of Health Economic Evaluations in Submissions to Health Technology Assessment Agencies: How Systematic Are They, and Does This Matter?
deletePharmacoeconomics
IF4.6
delete2026-10-06
delete0
deleteOAAI
deleteChris Bartlett; Rachael McCool; Matthew Taylor
deleteShare
deleteSave
Meta-Analysis of Incremental Net Benefit from Trial-Based Health Economic Evaluations in R: A Tutorial
deletePharmacoeconomics
IF4.6
delete2026-09-30
delete0
deleteOAAI
deleteRomain Jonathan Collet; Johanna Maria van Dongen; Oraluck Pattanaprateep; Suparee Wisawapipat Boonmanunt; Ardine de Wit; Judith Ekkina Bosmans; Veerle Coupé; Raymond Ostelo; Ammarin Thakkinstian
deleteShare
deleteSave
Justifying and Classifying Adults’ Roles in Child Health State Valuation: A Novel Taxonomy
deletePharmacoeconomics
IF4.6
delete2026-09-30
delete0
deleteOAAI
deleteStefan A. Lipman; Vivian T. Reckers-Droog; Donna Rowen; Philip A. Powell
deleteShare
deleteSave
Modeling Framework for Economic Evaluation of Disease-Modifying Therapies in Parkinson’s Disease: Evidence Review and Expert Opinion
deletePharmacoeconomics
IF4.6
delete2026-09-30
delete0
deleteOAAI
deleteAnshul Shah; Richard Dodel; Saifuddin Kharawala; Katharina Klapper; Matthew May; Per Odin; Angelica Asis; Gennaro Pagano; Anna Kotzeva; Camille Carroll
deleteShare
deleteSave
Developing an Australian Value Set for the COCOON Carer Quality-of-Life Measure for Use in Economic Evaluations
deletePharmacoeconomics
IF4.6
delete2026-09-28
delete0
deleteOAAI
deleteLidia Engel; Cathrine Mihalopoulos; Nikki McCaffrey; Thao Thai
deleteShare
deleteSave
Derivation and Validation of Charlson, Elixhauser and RxRisk Cost-Based Comorbidity Indices: A Register-Based Study of 350,000 Individuals Over 11 Years
deletePharmacoeconomics
IF4.6
delete2026-09-22
delete0
deleteOAAI
deleteCamilla Nystrand; Naimi Johansson; Johannes Blom
deleteShare
deleteSave
Beyond Narrative and Tabular Synthesis: Introducing an Approach–Rationale–Note (ARN) Framework for Thematic Evidence Synthesis in Economic Evaluation Reviews
deletePharmacoeconomics
IF4.6
delete2026-09-17
delete0
deleteOAAI
deleteMehdi Yousefi; Amy Grove; Jo Parsons; Somayeh Fazaeli; Peter Auguste
deleteShare
deleteSave
A Systematic Review of Reporting of Validation Efforts for Cancer Health Economic Decision Models
deletePharmacoeconomics
IF4.6
delete2026-09-15
delete0
PREAI
deletePingping Li; Min Zhao; Yihe Tian; Hualing Yan; Huayu Sun; Hongchao Li
deleteShare
deleteSave
Estimating the Healthcare Cost of Infection-Related Hospitalisations in Multiple Myeloma
deletePharmacoeconomics
IF4.6
delete2026-09-15
delete0
PREAI
deleteRainier Arnolda; Sara Carrillo de Albornoz; Laura Fanning; Adam Irving; Aleece MacPhail; Erica Wood; Zoe McQuilten; Andrew Spencer; Dennis Petrie
deleteShare
deleteSave
Carbon Emission Impact of Semaglutide in People with Obesity in the UK Using a Disease Modelling Approach
deletePharmacoeconomics
IF4.6
delete2026-09-10
delete0
PREAI
deleteNiels Lund; Christopher Lübker; Andreas Rasche; Matthew Taylor; Weiwei Xu; Loveleen Taneja; Suramya Shukla; Anamaria-Vera Olivieri; Yuvraj Sharma
deleteShare
deleteSave
Methods for Analysing Patient-Level Utility Data: Insights from the Literature Review and Recent NICE Technology Appraisals
deletePharmacoeconomics
IF4.6
delete2026-09-06
delete0
PREAI
deleteSaul Stevens; Maxwell S. Barnish; Alan Lovell; Frank Grimsey Jones; Jemma Perks; G. J. Melendez-Torres; Elham Nikram; Anthony Hatswell; Elsa Marques; Matthew Franklin; Dan Gallacher; Vanessa Buchanan; Dawn Lee
deleteShare
deleteSave
Value of Knowing the Risk of Developing a Neurodegenerative Disease: A Discrete Choice Experiment
deletePharmacoeconomics
IF4.6
delete2026-09-06
delete0
deleteOAAI
deletePatricia G. Synnott; Daniel A. Ollendorf; Steven M. Kymes; Donna L. Bernstein; Montserrat Vera-Llonch
deleteShare
deleteSave
Developing a Quality-of-Life Measure for Carers of People with Dementia for Use in Economic Evaluations: Results from the COCOON Project
deletePharmacoeconomics
IF4.6
delete2026-09-04
delete0
deleteOAAI
deleteLidia Engel; Briony Dow; Anne Muldowney; Cathrine Mihalopoulos; Julie Ratcliffe; Mark Yates; Rosemary Cameron; Irene Jones; Nikki McCaffrey
deleteShare
deleteSave
Bayesian Dynamic Borrowing to Enhance Evidence for New Therapies
deletePharmacoeconomics
IF4.6
delete2026-09-04
delete0
deleteOAAI
deleteSean Yiu; Katya Galactionova; Steven Yuen; Chris Skedgel; Isabelle Durand Zaleski; Maarten Postma; Mark Sculpher; Keith R. Abrams
deleteShare
deleteSave
Landscape Analysis of Literature Using Quantitative Approaches to Synthesize Economic Evaluation Studies: A Scoping Review
deletePharmacoeconomics
IF4.6
delete2026-09-04
delete0
PREAI
deleteSajesh K. Veettil; Christy Thomas; Chan Jia En; Manuel Meraz; Teerapon Dhippayom; Muhammed Rashid; Jeong-Yeon Cho; Ratree Sawangjit; Filip Meheus; Andrew Mirelman; Raymond Hutubessy; Nathorn Chaiyakunapruk
deleteShare
deleteSave
Correction: Balancing Access and Value in Multi‑Indication Medicines: Implications of PD‑(L)1 Broad Listings in Australia
deletePharmacoeconomics
IF4.6
delete2026-08-22
delete0
deleteOAAI
deleteIsaiah Luc; Drew Carter; Tracy Merlin
deleteShare
deleteSave
Missing Data in Trial-Based Cost-Effectiveness Analysis: The Journey Continues
deletePharmacoeconomics
IF4.6
delete2026-08-12
delete0
PREAI
deleteJiunn Wang; Baptiste Leurent; Manuel Gomes
deleteShare
deleteSave
Fail to Compare, Prepare to Fail: Comparator Omission in NICE Single Technology Appraisals
deletePharmacoeconomics
IF4.6
delete2026-08-07
delete0
PREAI
deleteFrank Grimsey Jones; Saul Stevens; Dawn Lee
deleteShare
deleteSave
The End of ‘Pay-and-Hope’: Managing Accelerated Approvals with Outcomes-Based Reimbursement in the Era of Routinely Collected Health Data
deletePharmacoeconomics
IF4.6
delete2026-08-06
delete0
PREAI
deleteGiovanni Tramonti; Peter S. Hall
deleteShare
deleteSave